Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming Louise O'Reilly .
Filed returns
27
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Life Sciences Strategy for Ireland (Public policy or programme) | 10 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Economic Development and Industry | Meeting requests on foot of 21st Century Infrastructure: Accelerating Delivery of the National Digital Strategy (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Economic Development and Industry | Sharing key policy documents with key stakeholders across Goverment (Public policy or programme) | 77 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Economic Development and Industry | Circulation of policy paper on '21st Century Infrastructure: Accelerating Delivery of the National Digital Strategy' (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Energy and Natural Resources | Ocean Winds' offshore wind projects in Ireland (Zoning or development) | 62 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Finance | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Finance | The impact of Covid-19 on the car rental industry (Public policy or programme) | 20 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 85 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 5 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | The impact of COVID-19 on the tourism sector in Ireland, and the specific impact it is having the Irish car rental industry (Legislation) | 20 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 13 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 18 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Rare Disease Medicines (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 19 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 19 | 70.4% | |
| Economic Development and Industry | 3 | 11.1% | |
| Finance | 2 | 7.4% | |
| Transport | 2 | 7.4% | |
| Energy and Natural Resources | 1 | 3.7% |